Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-003405

CHIEF FINANCIAL OFFICER sold 1,000 shares at $22.52 ($22,524)

  • CHIEF FINANCIAL OFFICER acquired 1,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hohl Benjamin · CHIEF FINANCIAL OFFICER

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2025-02-05 Exercise or conversion : show line 1 in the form 10b5-1 +1,000 $2.48 $2,480 14,000 D
2025-02-05 Sale : show line 2 in the form 10b5-1 −1,000 $22.52 $22,524 13,000 D
Open-market sales · 1,000 sh · avg $22.52 · $22,524

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2025-02-05 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) −1,000 146,056 D
Loading xslF345X05/form4-02082025_120242.xml…